US Stock MarketDetailed Quotes

SLRN Acelyrin

Watchlist

2.130
0.0000.00%

Close Feb 18 16:00 ET

2.130
0.0000.00%

Post 16:02 ET

213.69MMarket Cap-0.80P/E (TTM)

Acelyrin Stock Forum

Lnova

19 hours ago

T. Rowe Price Investment Management 12,851,050 shares, 12.8%
$Acelyrin (SLRN.US)$
has options
nfa

Acelyrin | SCHEDULE 13G/A: Others

Lnova

19 hours ago

Citadel Advisors 4,192,377 shares, 4.2%
$Acelyrin (SLRN.US)$
has options
nfa

Acelyrin | SCHEDULE 13G/A: Others

Jaguar8

Feb 6 20:51

🟠Watchlist, FEBRUARY 7,2025, Friday. NFA- DrJag8 (I am not sure if I’ll be trading tomorrow)

NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow...

Spiderrrman

Feb 6 16:10

2.27go

$Acelyrin (SLRN.US)$
Based on the provided information, Alumis Inc. (ALMS) and ACELYRIN, Inc. (SLRN) have announced a merger agreement. In this all-stock transaction, ACELYRIN stockholders will receive 0.4274 shares of Alumis common stock for each share of ACELYRIN common stock they own. Post-merger, Alumis stockholders will own approximately 55% of the combined company, while ACELYRIN stockholders will own about 45% on a fully diluted basis.
Estimating the Post-Merger Stock Price of Alu...

Trytosaveabit

Feb 6 15:29

T 1 Halt

$Acelyrin (SLRN.US)$ $Alumis (ALMS.US)$ Trading to resume at 16:45

Trytosaveabit

Feb 6 15:20

News

$Acelyrin (SLRN.US)$ $Alumis (ALMS.US)$ Reuters· 3 mins ago
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-Mediated Diseases

Jaguar8

Feb 6 15:15

NEWS

$Acelyrin (SLRN.US)$ $Alumis (ALMS.US)$
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
Thursday, 6th February at 4:15 pm
Topline data from Phase 3 ONWARD trials for Alumis' ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on track for readout i...